Tag results:
lymphocytes
Immunology of Infectious Disease News
EBNA2 Driven Enhancer Switching at the CIITA-DEXI Locus Suppresses HLA Class II Gene Expression during EBV Infection of B-Lymphocytes
[PLOS Pathogens] Investigators identified a major EBNA2 binding site downstream of the CIITA gene and upstream of DEXI, a dexamethasone inducible gene that is oriented head-to-head with CIITA gene transcripts.
Immunology of Infectious Disease News
Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients with Hematologic Malignancies
[Blood Cancer Journal] The authors evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies.
Umbilical & Placental Cell News
Allogeneic Hematopoietic Stem Cell Transplantation from Unmanipulated Haploidentical Donor and Unrelated Cord Blood for T-cell Lymphoma: A Retrospective Study from the Société Francophone De...
[Bone Marrow Transplantation] The authors evaluated the outcome of recipients of alternative donor allogeneic stem cell transplantation for T-cell lymphoma.
Pancreatic Cell News
Primary ALK-Positive Large B Cell Lymphoma of Pancreas
[Journal of Gastrointestinal Cancer] Biopsy revealed a lymphoma with strong expression of ALK (granular cytoplasmic), CD138, MUM1, kappa, moderate expression of CD45 and focal expression of CD20, CD79a and PAX5 and lack of expression of CD5, CD3, CD45RO, BCL6, CD10 and EMA.
Hepatic Cell News
Chemoprophylaxis Vaccination with a Plasmodium Liver Stage Autophagy Mutant Affords Enhanced and Long-Lasting Protection
[NPJ Vaccines] Scientists demonstrated that a liver stage-specific autophagy mutant of Plasmodium berghei, when used as a live vaccine under a chemoprophylaxis vaccination (CVac) regimen, provided superior long-lasting protection, in both inbred and outbred mice, as compared to WT-CVac.
Pancreatic Cell News
NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabetes
[NexImmune, Inc.] NexImmune, Inc. announced a collaboration with Yale University’s Department of Immunobiology. The collaboration will focus on the use of NexImmune’s direct injection, artificial antigen presenting cells with regards to the regulation of autoimmune diabetes (Type 1 diabetes). Dr. Kevan Herold, Deputy Director of Yale Center for Clinical Investigation and Co-Director of the Yale Diabetes Center will be the principal investigator.